General Updates

Emcure Ref: EPL/CS/SE/0080/2026 Date: September 01, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, P J Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai – 400 051 Mumbai - 400 001 Script Symbol: EMCURE Scrip Code/Symbol: 544210/ EMCURE Dear Sir/Madam, Subject: Intimation under Regulations 30 and 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Dispatch of letter to the Members whose e-mail addresses are not registered with the Company/Depository Participants. Pursuant to Regulations 30 and 36(1)(b) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that, the Company has dispatched a letter to those Members who have not registered their e-mail addresses with the Company/Depository Participants, providing a web-link (including the exact path) along with QR Code of the Annual Report 2025-26 and Notice of 45th Annual General Meeting of the Members of the Company to be held on Monday, September 21, 2026, through Video Conferencing facility / Other Audio Visual Means. A copy of the letter is enclosed herewith for your record. You are requested to take the above information on your records. Thanking you, For Emcure Pharmaceuticals Limited Amruta Yangalwar Company Secretary & Compliance Officer Membership Number: A25687 Encl: As above Emcure Pharmaceuticals Limited Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060 E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251 EMCURE PHARMACEUTICALS LIMITED CIN:L24231PN1981PLC024251 Regd. Office:Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone No. : +91 20 -35070033 / 35070000 E-mail id:investors@emcure.com Website:www.emcure.com -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Date :August 28, 2026 Sub.:Notice of 45thAnnual General Meeting (AGM) of the Members of Emcure Pharmaceuticals Limited and Annual Report for the Financial Year 2025-26. We are pleased to inform you that the 45th Annual General Meeting ('AGM') of the Members of Emcure Pharmaceuticals Limited (‘the Company’) is scheduled to be held on Monday, September 21, 2026 at 11.00 a.m. (IST) through Video Conferencing ('VC') facility / Other Audio Visual Means ('OAVM'). As per Regulation 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (‘SEBI Listing Regulations’), as amended, the web-link, including the exact path, where complete details of the Annual Report are available is required to be sent to those Member(s) who have not registered their email address(es) either with the Company or with any Depository or MUFG Intime India Private Limited (Formerly Link Intime India Private Limited), Registrar & Transfer Agent (RTA) of the Company. Accordingly, the web-link, including the exact path where complete details of the Notice of 45th AGM and Annual Report for the Financial Year 2025-26 are as under: Web-link of Notice of 45thAGM: https://www.emcure.com/wp-content/uploads/2026/08/Notice-of-45th-AGM–21st-Sept-2026.pdf Web-link of Annual Report 2025-26: https://www.emcure.com/wp-content/uploads/2026/08/Annual-Report-FY-2025-26.pdf This letter is being sent to those Member(s) who have not registered their email address(es) either with the Company or with any Depository or RTA of the Company as on the cut-off date i.e. as on August 21, 2026. TDS exemption: You are requested to submit duly filled and signed documents for FY 2026-27,via e-mail to Income.Tax@emcure.com on or before Monday, September14, 2026, to claim exemption from TDS on the Final Dividend for FY 2025-26 (subject to approval by shareholders in the AGM). This is also areminder to update KYC details pursuant to SEBI Master Circular No.SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/91 dated June 23, 2025, and to dematerialise physical securities.The circular issued by SEBI mandates all the listed companies to record PAN, Address with PIN code, Mobile Number, Bank Account details, Specimen Signature and choice of Nomination of security holders holding securities in physical mode. While updating email ID is optional, the security holders are requested to register email ID also to avail online services. This is applicable for all security holders holding securities in physical mode. The formats for choice of Nomination and Updation of KYC details viz; Forms ISR-1, ISR-2, ISR-3, SH-13, SH-14 and SEBI circulars are available on the RTA’s websiteas mentioned below: https://www.in.mpms.mufg.com>Resources > Downloads > KYC > Formats for KYC. The aforesaid SEBI Circular also mandates that security holders holding shares in physical mode whose folios do not have PAN, Choice of Nomination, Contact details, Bank Account details and Specimen Signature updated, shall be eligible for any payment including dividend, interest or redemption payment in respect of such folios, only through electronic mode with effect from April 01, 2024. Should you have any queries, please feel free to contact the investor relations department of our RTA at investor.helpdesk@in.mpms.mufg.com or + 91 20 26160084. Moreover, you are again requested to update your e-mail address at the earliest either through your depository participants for electronic holding or send a communication to us / our RTA to facilitate the updation to continue receiving all important information & documents thereafter and encourage Green Initiative. Thanking you, Yours faithfully, For Emcure Pharmaceuticals Limited Sd/- Amruta Yangalwar Company Secretary & Compliance Officer ICSI Membership No.: A25687